Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.
Lo Re V 3rd, Haynes K, Ming EE, Wood Ives J, Horne LN, Fortier K, Carbonari DM, Hennessy S, Cardillo S, Reese PP, Reddy KR, Margolis D, Apter A, Kimmel SE, Roy J, Freeman CP, Razzaghi H, Holick CN, Esposito DB, Van Staa TP, Bhullar H, Strom BL.
Lo Re V 3rd, et al. Among authors: van staa tp.
Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1202-15. doi: 10.1002/pds.3318. Epub 2012 Jul 5.
Pharmacoepidemiol Drug Saf. 2012.
PMID: 22763953